Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Figure 4

Pharmacotherapeutic targets for depression in reward neurocircuits. ^∗Agonist. ^∗∗Antagonist. ^∗∗∗Modulator. μ: µ-opioid receptor. δ: δ-opioid receptor. κ: κ-opioid receptor. CB1: cannabinoid receptor 1. CB2: cannabinoid receptor 2. TRPV1: transient receptor potential cation channel V1. Research on pharmacotherapeutic targets for depression in the reward system remains principally preclinical. Currently available results presume some potential clinical utility for these substances for the treatment of depression, with varying degrees of efficacy and differing pharmacological profiles.